PA8535901A1 - Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato - Google Patents

Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato

Info

Publication number
PA8535901A1
PA8535901A1 PA20018535901A PA8535901A PA8535901A1 PA 8535901 A1 PA8535901 A1 PA 8535901A1 PA 20018535901 A PA20018535901 A PA 20018535901A PA 8535901 A PA8535901 A PA 8535901A PA 8535901 A1 PA8535901 A1 PA 8535901A1
Authority
PA
Panama
Prior art keywords
subtipe
aspartate
methyl
formula
piperidine derivatives
Prior art date
Application number
PA20018535901A
Other languages
English (en)
Spanish (es)
Inventor
Brian Edward Kornberg
David Douglas Manning
Sham Shridhar Nikam
Ian Leslie Scott
Russell Andrew Lewthwaite
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8535901A1 publication Critical patent/PA8535901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PA20018535901A 2000-12-21 2001-12-21 Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato PA8535901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25783200P 2000-12-21 2000-12-21

Publications (1)

Publication Number Publication Date
PA8535901A1 true PA8535901A1 (es) 2002-08-29

Family

ID=22977943

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018535901A PA8535901A1 (es) 2000-12-21 2001-12-21 Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato

Country Status (13)

Country Link
US (1) US6642256B2 (enExample)
EP (1) EP1345935A2 (enExample)
JP (1) JP2004516295A (enExample)
AU (1) AU2002223968A1 (enExample)
BR (1) BR0116311A (enExample)
CA (1) CA2436699A1 (enExample)
HN (1) HN2001000280A (enExample)
MX (1) MXPA03004652A (enExample)
PA (1) PA8535901A1 (enExample)
PE (1) PE20020882A1 (enExample)
TN (1) TNSN01175A1 (enExample)
UY (1) UY27081A1 (enExample)
WO (1) WO2002050070A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
RU2387646C2 (ru) 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
JP5573307B2 (ja) * 2010-03-31 2014-08-20 Ｊｓｒ株式会社 感放射線性樹脂組成物、重合体及び化合物
CA2936749C (en) * 2010-06-11 2019-07-09 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
IL293319B1 (en) * 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
EP3595661A4 (en) * 2017-03-12 2020-08-19 Xiaodong Wang POLYCYCLIC AMINES USED AS MODULATORS OF OPIOID RECEPTOR
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
CN117466836B (zh) * 2023-11-14 2026-02-06 万华化学集团股份有限公司 一种合成烯丙基叔胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793653A1 (en) 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
DE19531321A1 (de) * 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE19739332C1 (de) * 1997-09-09 1998-11-26 Merck Patent Gmbh Piperidinylmethyloxazolidinon-Derivat
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
WO2000018763A2 (en) * 1998-09-29 2000-04-06 Neurogen Corporation 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands

Also Published As

Publication number Publication date
BR0116311A (pt) 2003-09-23
PE20020882A1 (es) 2002-09-28
US20030018021A1 (en) 2003-01-23
WO2002050070A3 (en) 2002-09-19
TNSN01175A1 (fr) 2005-11-10
EP1345935A2 (en) 2003-09-24
US6642256B2 (en) 2003-11-04
WO2002050070A2 (en) 2002-06-27
MXPA03004652A (es) 2003-09-05
AU2002223968A1 (en) 2002-07-01
JP2004516295A (ja) 2004-06-03
CA2436699A1 (en) 2002-06-27
UY27081A1 (es) 2002-07-31
HN2001000280A (es) 2002-01-30

Similar Documents

Publication Publication Date Title
MX9805032A (es) Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-asparatato de n-metilo, selectivos para el subtipo.
UY27081A1 (es) Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato
MX9805031A (es) Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-aspartato de n-metilo, selectivos para el subtipo.
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
ES2084361T3 (es) Derivados de quinuclidina.
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
WO2004056324A3 (en) Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
CY1111032T1 (el) Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων
BRPI0408988A (pt) composto de piperidinilamino-tieno[2,3-d]pirimidina
GT200100181A (es) Derivados de quinazolina como antagonistas adrenergicos alfa-1.
TW430662B (en) Benzene-condensed hetero ring derivatives and their uses
DE60003899D1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
JOP20210020A1 (ar) معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
MXPA02011926A (es) Ciclohexilaminas biciclicas y su uso como antagonistas de receptor de n-metil-d-aspartato.
CA2354606A1 (en) Azabicycloalkane derivatives and therapeutic uses thereof
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
IT1276167B1 (it) Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
BR0200988A (pt) Derivados de ciclohexilamina como antagonistas de subtipos seletivos de n-metil-d-aspartato
AU2001295837A1 (en) Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
WO2023183776A3 (en) Targeting sucnr1 to reduce neuroinflammation